Abstract
Mild cognitive impairment (MCI), and the amnestic subtype of MCI in particular, is the most recent concept used to describe the intermediary state between healthy aging and Alzheimers disease (AD). It is hoped that research focusing on MCI would yield markers for early identification of individuals with prodromal AD at such a pre-dementia stage when potential disease modifying therapies would be most efficacious. Magnetic resonance imaging (MRI) combined with various data analysis methods provides tools to investigate alterations in brain structure and function in vivo. Structurally, MCI is characterized by atrophy of the medial temporal lobe (MTL) structures such as the hippocampus and entorhinal cortex, and the amount of atrophy in MCI is intermediate between healthy aging and AD. Additionally, atrophy of the posteromedial cortices such as the posterior cingulum and precuneus as well as of the lateral temporal cortices has been reported. The pattern of atrophy appears to vary according to the subtype of MCI. Functional MRI studies in MCI, compared to healthy aging and AD, have demonstrated both increased and decreased MTL activity during encoding novel visually presented material. Differences in the MTL activation pattern in MCI subjects may relate to differences in the severity of cognitive decline. There is some evidence that increased MTL activity observed during encoding may be compensatory due to incipient atrophy in the MTL structures. The resting state (or, “default mode”) network, and the posteromedial cortical regions in particular, appear to malfunction in MCI. It is suggested that both altered MTL and posteromedial cortical function may be indicative of future cognitive decline from MCI to clinical AD.
Keywords: Alzheimer's disease, early detection, fMRI, medial temporal lobe, memory, volumetry, voxel-based morphometry
Current Alzheimer Research
Title: Structural and Functional MRI in Mild Cognitive Impairment
Volume: 6 Issue: 2
Author(s): Maija Pihlajamaki, Anne M. Jauhiainen and Hilkka Soininen
Affiliation:
Keywords: Alzheimer's disease, early detection, fMRI, medial temporal lobe, memory, volumetry, voxel-based morphometry
Abstract: Mild cognitive impairment (MCI), and the amnestic subtype of MCI in particular, is the most recent concept used to describe the intermediary state between healthy aging and Alzheimers disease (AD). It is hoped that research focusing on MCI would yield markers for early identification of individuals with prodromal AD at such a pre-dementia stage when potential disease modifying therapies would be most efficacious. Magnetic resonance imaging (MRI) combined with various data analysis methods provides tools to investigate alterations in brain structure and function in vivo. Structurally, MCI is characterized by atrophy of the medial temporal lobe (MTL) structures such as the hippocampus and entorhinal cortex, and the amount of atrophy in MCI is intermediate between healthy aging and AD. Additionally, atrophy of the posteromedial cortices such as the posterior cingulum and precuneus as well as of the lateral temporal cortices has been reported. The pattern of atrophy appears to vary according to the subtype of MCI. Functional MRI studies in MCI, compared to healthy aging and AD, have demonstrated both increased and decreased MTL activity during encoding novel visually presented material. Differences in the MTL activation pattern in MCI subjects may relate to differences in the severity of cognitive decline. There is some evidence that increased MTL activity observed during encoding may be compensatory due to incipient atrophy in the MTL structures. The resting state (or, “default mode”) network, and the posteromedial cortical regions in particular, appear to malfunction in MCI. It is suggested that both altered MTL and posteromedial cortical function may be indicative of future cognitive decline from MCI to clinical AD.
Export Options
About this article
Cite this article as:
Pihlajamaki Maija, Jauhiainen M. Anne and Soininen Hilkka, Structural and Functional MRI in Mild Cognitive Impairment, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602898
DOI https://dx.doi.org/10.2174/156720509787602898 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Current Drug Metabolism Comparing Age Effects in Normally and Extremely Highly Educated and Intellectually Engaged 65 - 80 Year-olds: Potential Protection from Deficit Through Educational and Intellectual Activities Across the Lifespan
Current Aging Science Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Daidzein and its Effects on Brain
Current Medicinal Chemistry Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry α-Synuclein- and MPTP-Generated Rodent Models of Parkinsons Disease and the Study of Extracellular Striatal Dopamine Dynamics: A Microdialysis Approach
CNS & Neurological Disorders - Drug Targets Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies
Recent Patents on Inflammation & Allergy Drug Discovery Lipoic Acid: A Novel Therapeutic Approach for Multiple Sclerosis and Other Chronic Inflammatory Diseases of the CNS
Endocrine, Metabolic & Immune Disorders - Drug Targets Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Rational Basis for the Use of Bergamot Essential Oil in Complementary Medicine to Treat Chronic Pain
Mini-Reviews in Medicinal Chemistry Role of Dietary Polyphenols in Attenuating Brain Edema and Cell Swelling in Cerebral Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: Medicinal Chemistry: Neurological and Endocrinological Disorders)
Medicinal Chemistry Peptides and their Metal Complexes in Neurodegenerative Diseases: from Structural Studies to Nanomedicine Prospects
Current Medicinal Chemistry Ginseng for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Topics in Medicinal Chemistry Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration
Current Vascular Pharmacology